Company / EPS (Diluted)
Protagonist Therapeutics, Inc. EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.05
FY2025
5-year range
-$2.71 / $4.23
FY2021-FY2025
Trend
-148.5%
vs FY2024
Sector context
#124 of 204
Health Care
What the data says
At $-2.05, Protagonist Therapeutics, Inc.'s eps (diluted) ranks #124 of 204 in the Health Care sector. Declined from $-1.39 to $-2.05 over the past 2 years.
Based on SEC 10-K filings.
-2.05 in FY2025.
Declined from $-1.39 to $-2.05 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#124 of 204 in Health CareTop 61% of 204This company -$2.05 Sector average -$0.89
▼
-129.1% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 148.5% year-over-year.
- Ranks #124 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2024.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.05 | -148.5% |
| FY2024 | $4.23 | +404.3% |
| FY2023 | -$1.39 | +46.5% |
| FY2022 | -$2.60 | +4.1% |
| FY2021 | -$2.71 | -41.1% |
| FY2020 | -$1.92 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026